What are the treatment options after trifluridine and tipiracil (Lancever) have failed?

Trifluridine tipiracil (Lonsurf/Lonsurf) is an important drug in the treatment of colorectal cancer, and its efficacy is critical to many patients. This drug combines two active ingredients, trifluridine and tipiracil, which inhibit the growth and division of cancer cells through unique mechanisms. However, although it exhibits significant therapeutic effects in many cases, not every patient benefits from it.

When trifluridine or tipiracil fails to achieve the desired therapeutic effect, patients and physicians may be faced with a common question: Are there other options? Since each patient's constitution and condition are different, their response to medications will naturally vary. Therefore, when trifluridine and tipiracil fail to achieve the desired therapeutic effect, doctors usually consider other treatment options.

First of all, depending on the patient's specific situation, doctors may adjust their treatment plan and choose other chemotherapy drugs. After all, the treatment of colorectal cancer often relies on the combined use of multiple drugs, through the synergy between different drugs, in order to find a more suitable treatment plan for the patient. Secondly, targeted therapeutic drugs for colorectal cancer are also an option worth considering. This type of drug inhibits tumor growth through specific molecular mechanisms and may show better efficacy in some patients. Doctors may choose appropriate targeted therapy drugs based on the patient's genetic test results and tumor characteristics.

Finally, if a patient meets certain criteria, participating in a clinical trial for colorectal cancer is an avenue worth exploring. Clinical trials are usually conducted to evaluate the efficacy and safety of new drugs or treatments. For patients who have not responded well to traditional treatment options, participating in a clinical trial may mean the opportunity to try new treatments, thereby bringing new hope to their treatment.